N/A
Completed N=621
Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)
Complicated Skin and Skin Structure Infections · Complicated Intra-abdominal Infections
Source: ClinicalTrials.gov NCT00683332 ↗
Enrolled (actual)
621
Serious AEs
0.8%
Results posted
Jul 2011
Primary outcomePrimary: Number of Participants With Spontaneous Adverse Events — 17 Participants
Summary
The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Spontaneous Adverse Events |
17 | — |
Eligibility Criteria
Inclusion Criteria
- All patients from the study center who received or will receive at least one dose of Tygacil according to the approved product indication.
Exclusion Criteria
- Previously discontinued Tygacil therapy due to significant safety concern.
Data sourced from ClinicalTrials.gov (NCT00683332). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.